Yu L. Rao
State Key Laboratory Of Molecular Oncology, MOE Key Laboratory Of Protein Sciences, MOE Key Laboratory Of Bioorganic Phosphorus Chemistry & Chemical Biology
Beijing, 100084, China
Beijing, 100084, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications
Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].
Journal: Cancer letters
Published: June 30, 2026
Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV-471.
Journal: Cancer innovation
Published: May 18, 2026
Correction to "Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug Resistant Mutants and Adverse Effects".
Journal: Journal of medicinal chemistry
Published: February 01, 2026
Destabilized calcium dynamics visualized using the genetically-coded probe GCaMPJ in intact hearts of Calstabin2-null mice.
Journal: Frontiers in physiology
Published: January 14, 2026
Caspase Recruitment Domain 6 (CARD6) is the therapeutic target of dihydroartemisinin for lupus nephritis based on Proteolysis Targeting Chimera (PROTAC) technology.
Journal: British journal of pharmacology
Published: May 22, 2025
FAK: A Potential Target for Cancer Therapy.
Journal: ACS medicinal chemistry letters
Published: March 31, 2025
BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis.
Journal: iScience
Published: January 08, 2025
Trans 10, cis 12-conjugated linoleic acid alleviates vascular fibrosis in obese mice.
Journal: Prostaglandins, leukotrienes, and essential fatty acids
Published: October 17, 2024
The application of PROTACs in immune-inflammation diseases.
Journal: Bioorganic & medicinal chemistry
Published: August 16, 2024
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.
Journal: Cancer letters
Published: March 13, 2024
Last Updated: 09/26/2026